Tanshinone IIA
metaboliteTanshinone IIA modulates macrophage function and reduces inflammatory injury in myocardial infarction.
Pathway placement
Cascade stepPlaque inflammation
Confidencelow
RationaleNatural compound with macrophage-targeting properties; anti-inflammatory in MI models; mechanism not mechanistically placed.
Also acts inLipid entry/oxidation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I43
C — confounder / Type-II71
A — assay feasibility42
E — evidence strength26
T1DI (composite)4
Specificity differential (R−C)-27.1
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- scRank infers drug-responsive cell types from untreated scRNA-seq data using a target-perturbed gene regulatory network.Cell reports. Medicine · 2024 · PMID 38754419 · doi